Trial Profile

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Apr 2018 Results (n=52) assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AC0010 published in the Journal of Thoracic Oncology
21 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
21 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com